Adiposs and Emovo each receive CHF 150'000
Summary
While Adiposs develops nanotechnologies to boost survival rates among millions of cancer patients, Emovo with its a robotic orthosis aims to help people who have difficulties using their hands. Adiposs, a spin-off from the University Geneva founded by Andrej Babic and Justyna Plewka, is developing ImageBAT, a breakthrough CT (computed tomography) contrast agent that is able to detect changes in body fat. ImageBAT is a game-changer for cachexia detection and diagnosis: It will provide a vastly superior and early result compared to today’s standard of care for the 9 million new cancer patients per year, a first market estimated at CHF 1.6 billion. In addition to the Venture Kick funds, the startup seeks to raise CHF 1 million by the fourth quarter of this year, then engage their medical network to start clinical trials in early 2021. Luca Randazzo, the founder, Product development and Clinical operations expert at Emovo, hopes the patent-pending tech will restore users’ independence and autonomy in daily life.